Clinical trials: Chronic Liver Disease (CLD)
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density…
- Conditions
- Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema
- Trial name
- NCT07326592
- Testing
- CE1226
- Where
- 2 sites in Denmark
- Volunteers
- 270 people
- Sponsor
- CSL Behring
Chronic Liver Disease (CLD)
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults
- Trial name
- NCT07521241
- Testing
- AD-230, AD-2301
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Chronic Liver Disease (CLD)
A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults
A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults
- Trial name
- NCT07618845
- Testing
- AD-230 (Fasted), AD-230 (Fed)
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Chronic Liver Disease (CLD), Healthy Volunteers
Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver Function
The aim of the study is to confirm that the new generation state of the art breath analyzer gives equivalent results to the previous model of the Exalenz breath analyzer.
- Trial name
- NCT02187601
- Testing
- MPBA System, BreathID
- Where
- Israel
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.